The diagnostic and differential diagnosis utility of cerebrospinal fluid α -synuclein levels in Parkinson's disease: A meta-analysis

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Zhou, Bo ^a   Wen, Min ^a   Yu, Wen Feng ^a   Zhang, Chun Lin ^a   Jiao, Ling ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER;

DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SHY DRAGER SYNDROME;

EID: 84939194020     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/567386     Document Type: Review

References (42)

1. J. M. Shulman, P. L. De Jager, and M. B. Feany, "Parkinsons disease: genetics and pathogenesis," Annual Review of Pathology, vol. 6, pp. 193-222, 2011.
2. P. Foulds, D. M. A. Mann, J. D. Mitchell, and D. Allsop, "Parkinson disease: progress towards a molecular biomarker for Parkinson disease," Nature Reviews Neurology, vol. 6, no. 7, pp. 359-361, 2010.
3. A. J. Lees, J. Hardy, and T. Revesz, "Parkinsons disease," The Lancet, vol. 373, no. 9680, pp. 2055-2066, 2009.
4. L. M. Bekris, I. F. Mata, and C. P. Zabetian, "The genetics of Parkinson disease," Journal of Geriatric Psychiatry and Neurology, vol. 23, no. 4, pp. 228-242, 2010.
5. Y. Wu, W. Le, and J. Jankovic, "Preclinical biomarkers of Parkinson disease," Archives of Neurology, vol. 68, no. 1, pp. 22-30, 2011.
6. L. Parnetti, A. Castrioto, D. Chiasserini et al. , "Cerebrospinal fluid biomarkers in Parkinson disease," Nature Reviews Neurology, vol. 9, no. 3, pp. 131-140, 2013.
7. M. G. Spillantini, M. L. Schmidt, V. M.-Y. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, "α-synuclein in Lewy bodies," Nature, vol. 388, no. 6645, pp. 839-840, 1997.
8. M. Eller and D. R. Williams, "Biological fluid biomarkers in neurodegenerative parkinsonism," Nature Reviews Neurology, vol. 5, no. 10, pp. 561-570, 2009.
9. B. Winner, R. Jappelli, S. K. Maji et al. , "In vivo demonstration that α-synuclein oligomers are toxic," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 10, pp. 4194-4199, 2011.
10. J. Xu, S.-Y. Kao, F. J. S. Lee, W. Song, L.-W. Jin, and B. A. Yankner, "Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease," Nature Medicine, vol. 8, no. 6, pp. 600-606, 2002.
11. B. Mollenhauer, E. Trautmann, B. Otte et al. , "alpha-synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system," Journal of Neural Transmission, vol. 119, no. 7, pp. 739-746, 2012.
12. K. E. Paleologou, C. L. Kragh, D. M. A. Mann et al. , "Detection of elevated levels of soluble α-synuclein oligomers in postmortem brain extracts from patients with dementia with Lewy bodies," Brain, vol. 132, no. 4, pp. 1093-1101, 2009.
13. M. J. Park, S.-M. Cheon, H.-R. Bae, S.-H. Kim, and J. W. Kim, "Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinsons disease," Journal of Clinical Neurology, vol. 7, no. 4, pp. 215-222, 2011.
14. S. P. Hozo, B. Djulbegovic, and I. Hozo, "Estimating the mean and variance from the median, range, and the size of a sample," BMC Medical Research Methodology, vol. 5, article 13, 2005.
15. L. Parnetti, L. Farotti, P. Eusebi et al. , "Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinsons disease," Frontiers in Aging Neuroscience, vol. 6, article 53, 2014.
16. L. Parnetti, D. Chiasserini, E. Persichetti et al. , "Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinsons disease," Movement Disorders, vol. 29, no. 8, pp. 1019-1027, 2014.
17. S. Mondello, R. Constantinescu, H. Zetterberg, U. Andreasson, B. Holmberg, and A. Jeromin, "CSF α-synuclein and UCHL1 levels in Parkinsons disease and atypical parkinsonian disorders," Parkinsonism and Related Disorders, vol. 20, no. 4, pp. 382-387, 2014.
18. K. D. Van Dijk, M. Bidinosti, A. Weiss, P. Raijmakers, H. W. Berendse, and W. D. J. van de Berg, "Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinsons disease are unrelated to clinical and imaging measures of disease severity," European Journal of Neurology, vol. 21, no. 3, pp. 388-394, 2014.
19. B. Mollenhauer, E. Trautmann, P. Taylor et al. , "Total CSF alphasynuclein is lower in de novo Parkinson patients than in healthy subjects," Neuroscience Letters, vol. 532, no. 1, pp. 44-48, 2013.
20. M. B. Aerts, R. A. J. Esselink, W. F. Abdo, B. R. Bloem, and M. M. Verbeek, "CSF α-synuclein does not differentiate between parkinsonian disorders," Neurobiology of Aging, vol. 33, no. 2, pp. 430. e1-430. e3, 2012.
21. Y. Wang, M. Shi, K. A. Chung et al. , "Phosphorylated α-synuclein in Parkinsons disease," Science Translational Medicine, vol. 4, no. 121, Article ID 121ra20, 2012.
22. M. Shi, J. Bradner, A. M. Hancock et al. , "Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression," Annals of Neurology, vol. 69, no. 3, pp. 570-580, 2011.
23. L. Parnetti, D. Chiasserini, G. Bellomo et al. , "Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinsons disease and degenerative dementias," Movement Disorders, vol. 26, no. 8, pp. 1428-1435, 2011.
24. B. Mollenhauer, J. J. Locascio, W. Schulz-Schaeffer, F. Sixel-Döring, C. Trenkwalder, and M. G. Schlossmacher, "alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study," The Lancet Neurology, vol. 10, no. 3, pp. 230-240, 2011.
25. Z. Hong, M. Shi, K. A. Chung et al. , "DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinsons disease," Brain, vol. 133, no. 3, pp. 713-726, 2010.
26. A. Öhrfelt, P. Grognet, N. Andreasen et al. , "Cerebrospinal fluid α-synuclein in neurodegenerative disorders-a marker of synapse loss? " Neuroscience Letters, vol. 450, no. 3, pp. 332-335, 2009.
27. O. Hansson, S. Hall, A. Ohrfelt et al. , "Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinsons disease with dementia and dementia with Lewy bodies compared to Alzheimers disease," Alzheimers Research and Therapy, vol. 6, no. 3, article 25, 2014.
28. T. Yasuda, Y. Nakata, and H. Mochizuki, "Alpha-synuclein and neuronal cell death," Molecular Neurobiology, vol. 47, no. 2, pp. 466-483, 2013.
29. I. Prots, V. Veber, S. Brey et al. , "α-synuclein oligomers impair neuronal microtubule-kinesin interplay," The Journal of Biological Chemistry, vol. 288, no. 30, pp. 21742-21754, 2013.
30. L. Devi, V. Raghavendran, B. M. Prabhu, N. G. Avadhani, and H. K. Anand atheerthavarada, "Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain," The Journal of Biological Chemistry, vol. 283, no. 14, pp. 9089-9100, 2008.
31. M. T. Ardah, K. E. Paleologou, G. Lv et al. , "Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity," Frontiers in Aging Neuroscience, vol. 6, article 197, 2014.
32. M. Periquet, T. Fulga, L. Myllykangas, M. G. Schlossmacher, and M. B. Feany, "Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo," Journal of Neuroscience, vol. 27, no. 12, pp. 3338-3346, 2007.
33. K. J. Spinelli, J. K. Taylor, V. R. Osterberg et al. , "Presynaptic alpha-synuclein aggregation in a mouse model of Parkinsons disease," Journal of Neuroscience, vol. 34, no. 6, pp. 2037-2050, 2014.
34. O. M. El-Agnaf, S. A. Salem, K. Paleologou et al. , "α-synuclein implicated in Parkinsons disease is present in extracellular biological fluids, including human plasma," The FASEB Journal, vol. 17, no. 13, pp. 1945-1947, 2003.
35. I. Devic, H. Hwang, J. S. Edgar et al. , "Salivary α-synuclein and DJ-1: potential biomarkers for Parkinsons disease," Brain, vol. 134, part 7, article e178, 2011.
36. K. D. van Dijk, C. E. Teunissen, B. Drukarch et al. , "Diagnostic cerebrospinal fluid biomarkers for Parkinsons disease: a pathogenetically based approach," Neurobiology ofDisease, vol. 39, no. 3, pp. 229-241, 2010.
37. B. Mollenhauer, O. M. A. El-Agnaf, K. Marcus, C. Trenkwalder, and M. G. Schlossmacher, "Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies," Biomarkers in Medicine, vol. 4, no. 5, pp. 683-689, 2010.
38. L. V. Kalia, S. K. Kalia, P. J. McLean, A. M. Lozano, and A. E. Lang, "Alpha-synuclein oligomers and clinical implications for parkinson disease," Annals of Neurology, vol. 73, no. 2, pp. 155-169, 2013.
39. M. R. Sierks, G. Chatterjee, C. McGraw, S. Kasturirangan, P. Schulz, and S. Prasad, "CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease," Integrative Biology, vol. 3, no. 12, pp. 1188-1196, 2011.
40. R. Barbour, K. Kling, J. P. Anderson et al. , "Red blood cells are the major source of alpha-synuclein in blood," Neurodegenerative Diseases, vol. 5, no. 2, pp. 55-59, 2008.
41. H. Zetterberg, M. Petzold, and N. Magdalinou, "Cerebrospinal fluid alpha-synuclein levels in Parkinsons disease-changed or unchanged? " European Journal of Neurology, vol. 21, no. 3, pp. 365-367, 2014.
42. L. Gao, H. Tang, K. Nie et al. , "Cerebrospinal fluid alphasynuclein as a biomarker for Parkinsons disease diagnosis: a systematic review and meta-analysis," International Journal of Neuroscience, 2014.